We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Barr Pharmaceuticals and Galen Holdings have finalized agreements that give Barr exclusive rights to Galen’s Loestrin oral contraceptive products and Galen the option to market Barr’s generic version of its own oral contraceptive Ovcon 35.
Boston Scientific is proving to be a fierce contender in the highly competitive coronary stent field. About two weeks after Boston Scientific launched its Taxus Express2 paclitaxel-eluting coronary stent system on March 4, the firm had rung up U.S. sales of about $42 million.
Generic firm Andrx has relinquished its 180-day exclusivity rights to the 150-mg strength version of GlaxoSmithKline’s antidepressant Wellbutrin SR (bupropion HCl extended-release) — a move that clears the way for final FDA approval of multiple generic competitors.
Generic competition on selective serotonin reuptake inhibitor (SSRI) products during the next decade will significantly limit growth in the major depression drug market in the U.S., according to a new study by Decision Resources.
India’s generic drugmakers are emerging as significant competitors in the global race to capture the more than $40 billion worth of brand drugs going off patent over the next few years, according to experts.
The Generic Pharmaceutical Association (GPhA) is putting the final touches on a nationwide generic drug awareness campaign that aims to dispel lingering misperceptions about the safety and effectiveness of the bioequivalent products.
More than two weeks after receiving FDA final approval, generic firms Sandoz and Alphapharm have yet to market their versions of GlaxoSmithKline’s (GSK’s) profitable antidepressant Paxil (paroxetine HCl).
The Senate has approved FDA Commissioner Mark McClellan’s nomination to head the Centers for Medicare & Medicaid Services (CMS), even as key senators predict Congress will pass legislation this year allowing for the reimportation of pharmaceuticals and negotiated prices for drugs purchased under Medicare.